Ajit Khanal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ajit Khanal has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Ananta Shrestha
1 shared publicationAnil Kumar Mishra
Bir Hospital, Kathmandu, Nepal
1 shared publication- Barun Shrestha
Gastroenterology, Chitwan Medical College, Bharatpur, NPL
1 shared publication - Bibek Purbey
Gastroenterology, Medicare Hospital Limited, Kathmandu, NPL
1 shared publication - Bidhan N. Paudel
Gastroenterology, National Academy of Medical Sciences, Kathmandu, NPL
1 shared publication Gaurav Shrestha
Gastroenterology, Annapurna Gastrocare Hospital, Nepalgunj, NPL
1 shared publication
Latest Publications
- Open Access
- 16 October 2025
- Published by Nepal Journals Online (JOL) in Journal of Society of Surgeons of Nepal
- Vol. 28 (1) , 15-18
Efficacy of Parenteral Cefotaxime Versus Combination of Piperacillin & Tazobactam as Empiric First Line Therapy in the Treatment of Spontaneous Bacterial Peritonitis
Introduction: Cefotaxime is the empiric antibiotic of choice for spontaneous bacterial peritonitis (SBP). However, rising gram-positive pathogen rates have prompted consideration of piperacillin-tazobactam as an alternative. This study compares their efficacy in treating SBP among cirrhotic patients. Methods: Thirty hospitalized cirrhotic patients diagnosed with SBP (ascitic fluid neutrophils > 250/mm3) were randomized into two groups: 15 received cefotaxime (2g IV twice daily), and 15 received Piperacilin-Tazobactam (4.5 g IV every eight hours), both for five days. More than 25% reduction in neutrophil count after 48 hours defined treatment response. Results: The response rate was 60% (9/15) in the cefotaxime group vs. 93.3% (14/15) in the piperacillin-tazobactam group (p=0.084). Among patients with prior SBP on quinolone prophylaxis, 75% receiving cefotaxime failed to respond, while 80% receiving Piperacillin-Tazobactam responded. Conclusion: Piperacillin/Tazobactam is as effective as Cefotaxime and may be superior in patients with prior SBP episodes on prophylaxis. These common clinical scenarios suggest Piperacillin-Tazobactam could be a more suitable empiric first line therapy for SBP in cirrhotic patients.
- 16 October 2025
- Published by Nepal Journals Online (JOL) in Journal of Society of Surgeons of Nepal
- Vol. 28 (1) , 15-18
Open AccessEfficacy of Parenteral Cefotaxime Versus Combination of Piperacillin & Tazobactam as Empiric First Line Therapy in the Treatment of Spontaneous Bacterial Peritonitis
Introduction: Cefotaxime is the empiric antibiotic of choice for spontaneous bacterial peritonitis (SBP). However, rising gram-positive pathogen rates have prompted consideration of piperacillin-tazobactam as an alternative. This study compares their efficacy in treating SBP among cirrhotic patients. Methods: Thirty hospitalized cirrhotic patients diagnosed with SBP (ascitic fluid neutrophils > 250/mm3) were randomized into two groups: 15 received cefotaxime (2g IV twice daily), and 15 received Piperacilin-Tazobactam (4.5 g IV every eight hours), both for five days. More than 25% reduction in neutrophil count after 48 hours defined treatment response. Results: The response rate was 60% (9/15) in the cefotaxime group vs. 93.3% (14/15) in the piperacillin-tazobactam group (p=0.084). Among patients with prior SBP on quinolone prophylaxis, 75% receiving cefotaxime failed to respond, while 80% receiving Piperacillin-Tazobactam responded. Conclusion: Piperacillin/Tazobactam is as effective as Cefotaxime and may be superior in patients with prior SBP episodes on prophylaxis. These common clinical scenarios suggest Piperacillin-Tazobactam could be a more suitable empiric first line therapy for SBP in cirrhotic patients.
- Open Access
- 31 December 2024
- Published by Nepal Journals Online (JOL) in Journal of Society of Surgeons of Nepal
- Vol. 27 (2) , 48-52
Endoscopic Findings In Patients Undergoing Upper Gastrointestinal Endoscopy For Various Indications: A Retrospective Study
Introduction: Upper gastrointestinal (UGI) endoscopy is a safe procedure performed for analysis of indications and findings in patient presenting with various gastrointestinal symptoms including dyspepsia. This study aimed to evaluate the findings of UGI endoscopy in a tertiary care level hospital in Kathmandu. Methods: A retrospective cross-sectional observational study of consecutive patients who had undergone UGI endoscopy at Department of Gastroenterology, Alka Hospital over a period of nine years (2016-2024) was conducted. Data was extracted from the records of the patients including demographic, clinical presentation, indications and findings and was analysed using SPSS version 30. Results: Eight thousand five hundred and fifty-two patients who underwent UGI endoscopy for dyspepsia and various other indications were included for the study, 4339 (50.7%) males, 4213 (49.3%) females, age range of 2-103years (mean age ± SD = 45.80 ± 15.38). The most common finding seen were gastritis 4298(50.3%), gastro-duodenitis 560 (6.5%), gastric ulcer 429 (5%), duodenal ulcer 276 (3.2%), duodenitis 277 (3.23%), oesophagitis 170 (2%), hiatus hernia 194 (2.22%), gastric polyp 153 (1.8%), oesophageal varices 100 (1.2%), gastrointestinal malignancy (0.78%) and no lesions; that is normal findings in 1687 (19.7%). Conclusion: UGI endoscopy is a relatively safe procedure and is performed for various indications including the commonest presentation of dyspepsia. Gastritis was the most common finding followed by Gastroduodenitis, Gastric and duodenal ulcers, Duodenitis, Hiatus Hernia, esophagitis, Polyps, Esophageal varices and Malignancy, while one-fifth of those undergoing the procedure had functional dyspepsia with normal findings.
- 31 December 2024
- Published by Nepal Journals Online (JOL) in Journal of Society of Surgeons of Nepal
- Vol. 27 (2) , 48-52
Open AccessEndoscopic Findings In Patients Undergoing Upper Gastrointestinal Endoscopy For Various Indications: A Retrospective Study
Introduction: Upper gastrointestinal (UGI) endoscopy is a safe procedure performed for analysis of indications and findings in patient presenting with various gastrointestinal symptoms including dyspepsia. This study aimed to evaluate the findings of UGI endoscopy in a tertiary care level hospital in Kathmandu. Methods: A retrospective cross-sectional observational study of consecutive patients who had undergone UGI endoscopy at Department of Gastroenterology, Alka Hospital over a period of nine years (2016-2024) was conducted. Data was extracted from the records of the patients including demographic, clinical presentation, indications and findings and was analysed using SPSS version 30. Results: Eight thousand five hundred and fifty-two patients who underwent UGI endoscopy for dyspepsia and various other indications were included for the study, 4339 (50.7%) males, 4213 (49.3%) females, age range of 2-103years (mean age ± SD = 45.80 ± 15.38). The most common finding seen were gastritis 4298(50.3%), gastro-duodenitis 560 (6.5%), gastric ulcer 429 (5%), duodenal ulcer 276 (3.2%), duodenitis 277 (3.23%), oesophagitis 170 (2%), hiatus hernia 194 (2.22%), gastric polyp 153 (1.8%), oesophageal varices 100 (1.2%), gastrointestinal malignancy (0.78%) and no lesions; that is normal findings in 1687 (19.7%). Conclusion: UGI endoscopy is a relatively safe procedure and is performed for various indications including the commonest presentation of dyspepsia. Gastritis was the most common finding followed by Gastroduodenitis, Gastric and duodenal ulcers, Duodenitis, Hiatus Hernia, esophagitis, Polyps, Esophageal varices and Malignancy, while one-fifth of those undergoing the procedure had functional dyspepsia with normal findings.
- Open Access
- 28 July 2021
- Published by Springer Nature in Cureus
- Vol. 13 (7)
Epidemiology of Inflammatory Bowel Diseases in Nepal
Inflammatory bowel diseases (IBD) comprise ulcerative colitis (UC) and Crohn's disease (CD). These are diseases of the gastrointestinal tract without a clear etiology but have strong relationships with underlying factors like genetic susceptibility, environmental factors, and intestinal bacteria. In the east, inflammatory bowel diseases predominantly affect the younger population and have an almost equal gender distribution. With urbanization and the adoption of the western lifestyle, the incidence and prevalence of IBD are increasing in Asia. In this study, we describe the epidemiology of IBD in Nepal. This was an observational study conducted in nine endoscopy centers within Nepal. Two years of data of colonoscopies in these centers were collected retrospectively. IBD was diagnosed by endoscopic examination. The incidence of IBD was calculated as the number of patients with IBD per 1000 colonoscopies per year. The demographic profiles of the patients were also collected. A total of 7526 colonoscopies were done in nine centers within the two years study period. IBD was seen in 479 patients (6.3%). The incidence of UC was 23.7 per 1000 colonoscopies per year and the incidence of CD was 1.6 per 1000 colonoscopies per year. UC (87%) was more common than CD (13%). Both UC and CD were mostly seen in the 30 to 40 years age group. In patients with UC, the rectum was the most commonly affected site. IBD in Nepal affects young males in their thirties. Younger age of affliction with a chronic disease and lack of awareness regarding the symptoms and diagnostic modalities of IBD may result in a delayed diagnosis. The target population must be made aware of the presenting symptoms of IBD and a need for colonoscopic examination for diagnosis. There is also a need for creating a national IBD registry for Nepal.
- 28 July 2021
- Published by Springer Nature in Cureus
- Vol. 13 (7)
Open AccessEpidemiology of Inflammatory Bowel Diseases in Nepal
Inflammatory bowel diseases (IBD) comprise ulcerative colitis (UC) and Crohn's disease (CD). These are diseases of the gastrointestinal tract without a clear etiology but have strong relationships with underlying factors like genetic susceptibility, environmental factors, and intestinal bacteria. In the east, inflammatory bowel diseases predominantly affect the younger population and have an almost equal gender distribution. With urbanization and the adoption of the western lifestyle, the incidence and prevalence of IBD are increasing in Asia. In this study, we describe the epidemiology of IBD in Nepal. This was an observational study conducted in nine endoscopy centers within Nepal. Two years of data of colonoscopies in these centers were collected retrospectively. IBD was diagnosed by endoscopic examination. The incidence of IBD was calculated as the number of patients with IBD per 1000 colonoscopies per year. The demographic profiles of the patients were also collected. A total of 7526 colonoscopies were done in nine centers within the two years study period. IBD was seen in 479 patients (6.3%). The incidence of UC was 23.7 per 1000 colonoscopies per year and the incidence of CD was 1.6 per 1000 colonoscopies per year. UC (87%) was more common than CD (13%). Both UC and CD were mostly seen in the 30 to 40 years age group. In patients with UC, the rectum was the most commonly affected site. IBD in Nepal affects young males in their thirties. Younger age of affliction with a chronic disease and lack of awareness regarding the symptoms and diagnostic modalities of IBD may result in a delayed diagnosis. The target population must be made aware of the presenting symptoms of IBD and a need for colonoscopic examination for diagnosis. There is also a need for creating a national IBD registry for Nepal.